AAN 2025 | The NETSseq platform: identifying novel targets for the treatment of Parkinson’s disease
Stuart Isaacson, MD, Director of the Parkinson’s Disease and Movement Disorders Center of Boca Raton, Boca Raton, FL, comments on the NETSseq platform, which uses artificial intelligence to identify novel drug targets for the treatment of Parkinson’s disease. Using this platform, GPR6 was identified as a promising new target, and the drug solengrepas is currently being investigated to act on this receptor. This interview took place at the 77th American Academy of Neurology (AAN) Annual Meeting in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Well, we have a lot of treatments for Parkinson’s disease already approved to help our patients now, many in development that patients have access to in clinical trials. And we’re always looking for new treatments, novel mechanisms that can help us treat both the motor and the non-motor symptoms better than we can now. And a lot of different ways of identifying novel medications that might be helpful have been sought...
Well, we have a lot of treatments for Parkinson’s disease already approved to help our patients now, many in development that patients have access to in clinical trials. And we’re always looking for new treatments, novel mechanisms that can help us treat both the motor and the non-motor symptoms better than we can now. And a lot of different ways of identifying novel medications that might be helpful have been sought. This company, Cerevance, has this proprietary NetSeq platform that’s really designed to identify novel drug targets for Parkinson’s disease and then for other neurodegenerative and other CNS disorders. And it really goes by trying to isolate individual cell types, isolating and purifying their nuclei, looking at the genomic and epigenomic phenomena that occur within these nuclei, and then using AI and machine learning to really refine and get insights into what of these genomics and multi-omics type of high-level data can inform us of what might be a novel target. And in this way, target selection can be informed and be novel and then be tested in animals and then in humans in early and then later trials. And this is how solengepras was actually identified. This is a novel mechanism because it really targets and inhibits a protein, a membrane protein, a receptor called GPR6. That’s really a novel target, hasn’t been looked at before, and is really an interesting target for a number of reasons in Parkinson’s disease.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
